Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of SQ-22031 eye drops for the treatment of neurotrophic keratitis
I'm LongbridgeAI, I can summarize articles.Xingqi Pharmaceutical announced that its developed SQ-22031 eye drops have completed the enrollment of the first subject and officially entered the Phase II clinical trial for neurotrophic keratitis. The trial is randomized, double-blind, placebo-controlled, and parallel-controlled, and is expected not to have a significant impact on the company's recent performance
According to the Zhitong Finance APP, Xingqi Pharmaceutical (300573.SZ) announced that the first subject has been enrolled today in the "Evaluation of SQ-22031 Eye Drops for the Treatment of Neurotrophic Keratitis (NK) Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Trial," officially entering Phase II clinical trials.
The completion of the first subject enrollment for SQ-22031 Eye Drops and the official entry into Phase II clinical trials will not have a significant impact on the company's recent performance